Align Technology ((ALGN)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Align Technology is conducting a clinical study titled ‘Hyrax Vs. Invisalign Palatal Expander Clinical Study’ to compare the expansion results and overall experience between the Invisalign Palatal Expander and the Hyrax expander. This study aims to address conditions such as malocclusions and narrow maxillary arches, which are significant in orthodontic treatment.
The study tests two interventions: the Removable Rapid Palatal Expander, used with Invisalign, and the Banded Palatal Expander, known as Hyrax. Both are devices designed to expand the palate, but they differ in application methods.
This interventional study is randomized with a parallel assignment model and no masking, focusing primarily on treatment. Such a design ensures unbiased comparison between the two devices.
The study began on October 22, 2024, with the latest update on December 2, 2024. These dates indicate the study’s active recruitment phase, which is crucial for data collection and subsequent analysis.
For investors, this study could impact Align Technology’s stock performance by potentially enhancing its product offerings and competitive position in the orthodontic market. The outcome may influence investor sentiment, especially if the Invisalign expander shows favorable results compared to traditional methods.
The study is ongoing, with further details available on the ClinicalTrials portal.